{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:58:53Z","timestamp":1790261933206,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma (GBM) is one of the most aggressive types of cancer, which begins within the brain. It is the most invasive type of glioma developed from astrocytes. Until today, Temozolomide (TMZ) is the only standard chemotherapy for patients with GBM. Even though chemotherapy extends the survival of patients, there are many undesirable side effects, and most cases show resistance to TMZ. FL3 is a synthetic flavagline which displays potent anticancer activities, and is known to inhibit cell proliferation, by provoking cell cycle arrest, and leads to apoptosis in a lot of cancer cell lines. However, the effect of FL3 in glioblastoma cancer cells has not yet been examined. Hypoxia is a major problem for patients with GBM, resulting in tumor resistance and aggressiveness. In this study, we explore the effect of FL3 in glioblastoma cells under normoxia and hypoxia conditions. Our results clearly indicate that this synthetic flavagline inhibits cell proliferation and induced senescence in glioblastoma cells cultured under both conditions. In addition, FL3 treatment had no effect on human brain astrocytes. These findings support the notion that the FL3 molecule could be used in combination with other chemotherapeutic agents or other therapies in glioblastoma treatments.<\/jats:p>","DOI":"10.1038\/s41598-020-70820-6","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T10:06:45Z","timestamp":1597313205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes"],"prefix":"10.1038","volume":"10","author":[{"given":"Ezeddine","family":"Harmouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Seitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Chaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Ubeaud-Sequier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Barths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"D\u00e9saubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Grandemange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Massfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Fioretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Dontenwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Benkirane-Jessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ysia","family":"Idoux-Gillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"issue":"9","key":"70820_CR1","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chembiol.2012.07.012","volume":"19","author":"G Polier","year":"2012","unstructured":"Polier, G. et al. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol.19(9), 1093\u20131104 (2012).","journal-title":"Chem. Biol."},{"issue":"11","key":"70820_CR2","doi-asserted-by":"crossref","first-page":"e0141826","DOI":"10.1371\/journal.pone.0141826","volume":"10","author":"R Qureshi","year":"2015","unstructured":"Qureshi, R. et al. FL3, a synthetic flavagline and ligand of prohibitins, protects cardiomyocytes via STAT3 from doxorubicin toxicity. PLoS ONE10(11), e0141826 (2015).","journal-title":"PLoS ONE"},{"key":"70820_CR3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1039\/c39820001150","volume":"20","author":"ML King","year":"1982","unstructured":"King, M. L. et al. X-ray crystal structure of rocaglamide, a novel antileulemic 1 H-cyclopenta [b] benzofuran from Aglaia elliptifolia. J. Chem. Soc. Chem. Commun.20, 1150\u20131151 (1982).","journal-title":"J. Chem. Soc. Chem. Commun."},{"issue":"18","key":"70820_CR4","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4155\/fmc.13.177","volume":"5","author":"C Basmadjian","year":"2013","unstructured":"Basmadjian, C., Thuaud, F., Ribeiro, N. & D\u00e9saubry, L. Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A. Future Med. Chem.5(18), 2185\u20132197 (2013).","journal-title":"Future Med. Chem."},{"issue":"1","key":"70820_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13046-018-0695-5","volume":"37","author":"G Yuan","year":"2018","unstructured":"Yuan, G. et al. Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt\/PHB interaction to activate the GADD45\u03b1 pathway. J. Exp. Clin. Cancer Res.37(1), 21 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"70820_CR6","doi-asserted-by":"crossref","first-page":"e1660","DOI":"10.1038\/cddis.2015.40","volume":"6","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell Death Dis.6(2), e1660\u2013e1660 (2015).","journal-title":"Cell Death Dis."},{"key":"70820_CR7","first-page":"1","volume":"15","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases. Cell. Mol. Life Sci.15, 1\u201322 (2020).","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"70820_CR8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/0006-291X(89)91813-5","volume":"164","author":"JK McClung","year":"1989","unstructured":"McClung, J. K. et al. Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver. Biochem. Biophys. Res. Commun.164(3), 1316\u20131322 (1989).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"70820_CR9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2014.02.020","volume":"89","author":"F Emhemmed","year":"2014","unstructured":"Emhemmed, F. et al. Selective anticancer effects of a synthetic flavagline on human Oct4-expressing cancer stem-like cells via a p38 MAPK-dependent caspase-3-dependent pathway. Biochem. Pharmacol.89(2), 185\u2013196 (2014).","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"70820_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/15548627.2019.1628520","volume":"16","author":"C Yan","year":"2020","unstructured":"Yan, C. et al. PHB2 (prohibitin 2) promotes PINK1-PRKN\/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. Autophagy16(3), 419\u2013434 (2020).","journal-title":"Autophagy"},{"issue":"1","key":"70820_CR11","first-page":"3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M. & Simjee, S. U. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac. J. Cancer Prev. APJCP18(1), 3 (2017).","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"2","key":"70820_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/BST20180444","volume":"47","author":"SL Perrin","year":"2019","unstructured":"Perrin, S. L. et al. Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochem. Soc. Trans.47(2), 625\u2013638 (2019).","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"70820_CR13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/neuonc\/nos153","volume":"14","author":"PA R\u00f8nning","year":"2012","unstructured":"R\u00f8nning, P. A., Helseth, E., Meling, T. R. & Johannesen, T. B. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-oncology14(9), 1178\u20131184 (2012).","journal-title":"Neuro-oncology"},{"key":"70820_CR14","first-page":"104","volume":"14","author":"RA Kore","year":"2018","unstructured":"Kore, R. A. et al. Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. Biochem. Biophys. Rep.14, 104\u2013113 (2018).","journal-title":"Biochem. Biophys. Rep."},{"key":"70820_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-69194-7_7","volume-title":"Stem Cell Microenvironments and Beyond","author":"A Sattiraju","year":"2017","unstructured":"Sattiraju, A., Sai, K. K. S. & Mintz, A. Glioblastoma stem cells and their microenvironment. In Stem Cell Microenvironments and Beyond (ed. Birbrair, A.) 119\u2013140 (Springer, Cham, 2017)."},{"issue":"19","key":"70820_CR16","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.yexcr.2012.07.017","volume":"318","author":"L Yang","year":"2012","unstructured":"Yang, L., Lin, C., Wang, L., Guo, H. & Wang, X. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp. Cell Res.318(19), 2417\u20132426 (2012).","journal-title":"Exp. Cell Res."},{"issue":"2","key":"70820_CR17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","volume":"7","author":"B Kaur","year":"2005","unstructured":"Kaur, B. et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology7(2), 134\u2013153 (2005).","journal-title":"Neuro-oncology"},{"issue":"4","key":"70820_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"A Monteiro","year":"2017","unstructured":"Monteiro, A., Hill, R., Pilkington, G. & Madureira, P. The role of hypoxia in glioblastoma invasion. Cells6(4), 45 (2017).","journal-title":"Cells"},{"issue":"1","key":"70820_CR19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3892\/ol.2017.6221","volume":"14","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. Epidermal growth factor receptor in glioblastoma. Oncol. Lett.14(1), 512\u2013516 (2017).","journal-title":"Oncol. Lett."},{"issue":"1","key":"70820_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sigtrans.2017.40","volume":"2","author":"JR Pearson","year":"2017","unstructured":"Pearson, J. R. & Regad, T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct. Target. Ther.2(1), 1\u201311 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"70820_CR21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2990.2002.00391.x","volume":"28","author":"KL S\u00f8ndergaard","year":"2002","unstructured":"S\u00f8ndergaard, K. L., Hilton, D. A., Penney, M., Ollerenshaw, M. & Demaine, A. G. Expression of hypoxia inducible factor 1\u03b1 in tumours of patients with glioblastoma. Neuropathol. Appl. Neurobiol.28(3), 210\u2013217 (2002).","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"70820_CR22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","volume":"38","author":"R Vengoji","year":"2019","unstructured":"Vengoji, R. et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J. Exp. Clin. Cancer Res.38(1), 266 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"70820_CR23","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1078-0432.CCR-14-2298","volume":"21","author":"JK Saggar","year":"2015","unstructured":"Saggar, J. K. & Tannock, I. F. Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation\u2014an effect that is inhibited by the hypoxia-activated prodrug TH-302. Clin. Cancer Res.21(9), 2107\u20132114 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"70820_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4110\/in.2016.16.3.183","volume":"16","author":"KB Yoon","year":"2016","unstructured":"Yoon, K. B., Park, K. R., Kim, S. Y. & Han, S. Y. Induction of nuclear enlargement and senescence by sirtuin inhibitors in glioblastoma cells. Immune Netw.16(3), 183\u2013188 (2016).","journal-title":"Immune Netw."},{"key":"70820_CR25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/sj.leu.2403141","volume":"17","author":"Y Huang","year":"2003","unstructured":"Huang, Y. et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1 \u03b1. Leukemia17, 2065\u20132073 (2003).","journal-title":"Leukemia"},{"issue":"2\u20133","key":"70820_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2004.06.069","volume":"371","author":"JY Jung","year":"2004","unstructured":"Jung, J. Y. & Kim, W. J. Involvement of mitochondrial-and Fas-mediated dual mechanism in CoCl2-induced apoptosis of rat PC12 cells. Neurosci. Lett.371(2\u20133), 85\u201390 (2004).","journal-title":"Neurosci. Lett."},{"issue":"3","key":"70820_CR27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0009-2797(98)00073-8","volume":"115","author":"SK Lee","year":"1998","unstructured":"Lee, S. K., Cui, B., Mehta, R. R., Kinghorn, A. D., & Pezzuto, J. M. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta [b] benzofuran lignans isolated from Aglaiaelliptica. Chem. Biol. Interact., 115(3), 215\u2013228 (1998).","journal-title":"Chem. Biol. Interact."},{"issue":"6","key":"70820_CR28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ijc.20033","volume":"109","author":"B Hausott","year":"2004","unstructured":"Hausott, B., Greger, H., & Marian, B. Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells. Int. J. Cancer, 109(6), 933\u2013940 (2004).","journal-title":"Int. J. Cancer"},{"issue":"4","key":"70820_CR29","doi-asserted-by":"crossref","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","volume":"4","author":"R Cencic","year":"2009","unstructured":"Cencic, R. et al. Antitumor activity and mechanism of action of the cyclopenta [b] benzofuran, silvestrol. PLoS ONE4(4), e5223 (2009).","journal-title":"PLoS ONE"},{"issue":"16","key":"70820_CR30","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1021\/jm900365v","volume":"52","author":"F Thuaud","year":"2009","unstructured":"Thuaud, F. et al. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12. J. Med. Chem.52(16), 5176\u20135187 (2009).","journal-title":"J. Med. Chem."},{"issue":"5","key":"70820_CR31","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.3390\/molecules19055981","volume":"19","author":"HY Park","year":"2014","unstructured":"Park, H. Y. et al. Fucoidan inhibits the proliferation of human urinary bladder cancer T24 cells by blocking cell cycle progression and inducing apoptosis. Molecules19(5), 5981\u20135998 (2014).","journal-title":"Molecules"},{"issue":"6B","key":"70820_CR32","first-page":"4197","volume":"25","author":"SC Brauns","year":"2005","unstructured":"Brauns, S. C., Dealtry, G., Milne, P., Naud\u00e9, R. & Van de venter, M. A. Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide cyclo (Phe-Pro) in HT-29 cells. Anticancer Res.25(6B), 4197\u20134202 (2005).","journal-title":"Anticancer Res."},{"key":"70820_CR33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol.75, 685\u2013705 (2013).","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"70820_CR34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1101\/gad.290635.116","volume":"31","author":"B Ritschka","year":"2017","unstructured":"Ritschka, B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev.31(2), 172\u2013183 (2017).","journal-title":"Genes Dev."},{"key":"70820_CR35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Revi. Pathol. Mech. Dis.5, 99\u2013118 (2010).","journal-title":"Annu. Revi. Pathol. Mech. Dis."},{"issue":"6","key":"70820_CR36","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cell.2017.05.015","volume":"169","author":"S He","year":"2017","unstructured":"He, S. & Sharpless, N. E. Senescence in health and disease. Cell169(6), 1000\u20131011 (2017).","journal-title":"Cell"},{"issue":"1","key":"70820_CR37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","volume":"79","author":"D Aasland","year":"2019","unstructured":"Aasland, D. et al. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR\u2013CHK1, p21, and NF-\u03baB. Cancer Res.79(1), 99\u2013113 (2019).","journal-title":"Cancer Res."},{"issue":"5","key":"70820_CR38","first-page":"1957","volume":"61","author":"Y Hirose","year":"2001","unstructured":"Hirose, Y., Berger, M. S. & Pieper, R. O. p53 effects both the duration of G2\/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res.61(5), 1957\u20131963 (2001).","journal-title":"Cancer Res."},{"key":"70820_CR39","doi-asserted-by":"crossref","first-page":"A102.1","DOI":"10.1136\/esmoopen-2018-EACR25.245","volume":"3","author":"M Christmann","year":"2018","unstructured":"Christmann, M., Aasland, D., Roos, W., Kaina, B. & Tomicic, M. PO-210 anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity. ESMO Open3, A102.1-A102 (2018).","journal-title":"ESMO Open"},{"issue":"1","key":"70820_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12885-015-1988-0","volume":"16","author":"WL Chen","year":"2016","unstructured":"Chen, W. L., Pan, L., Kinghorn, A. D., Swanson, S. M. & Burdette, J. E. Silvestrol induces early autophagy and apoptosis in human melanoma cells. BMC Cancer16(1), 17 (2016).","journal-title":"BMC Cancer"},{"issue":"1\u20132","key":"70820_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/B:MCBI.0000049134.69131.89","volume":"266","author":"M Valko","year":"2004","unstructured":"Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J. & Telser, J. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem.266(1\u20132), 37\u201356 (2004).","journal-title":"Mol. Cell. Biochem."},{"issue":"10","key":"70820_CR42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/07357907.2016.1245317","volume":"34","author":"H Manoochehri Khoshinani","year":"2016","unstructured":"Manoochehri Khoshinani, H., Afshar, S. & Najafi, R. Hypoxia: a double-edged sword in cancer therapy. Cancer Investig.34(10), 536\u2013545 (2016).","journal-title":"Cancer Investig."},{"issue":"3","key":"70820_CR43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","volume":"14","author":"N Rohwer","year":"2011","unstructured":"Rohwer, N. & Cramer, T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updates14(3), 191\u2013201 (2011).","journal-title":"Drug Resist. Updates"},{"issue":"1","key":"70820_CR44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","volume":"107","author":"AC Epstein","year":"2001","unstructured":"Epstein, A. C. et al.C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell107(1), 43\u201354 (2001).","journal-title":"Cell"},{"issue":"1","key":"70820_CR45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13036-018-0106-7","volume":"12","author":"HR Lee","year":"2018","unstructured":"Lee, H. R., Leslie, F. & Azarin, S. M. A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J. Biol. Eng.12(1), 12 (2018).","journal-title":"J. Biol. Eng."},{"issue":"2","key":"70820_CR46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3892\/or.2014.3235","volume":"32","author":"YY Wan","year":"2014","unstructured":"Wan, Y. Y. et al. Involvement of Drp1 in hypoxia-induced migration of human glioblastoma U251 cells. Oncol. Rep.32(2), 619\u2013626 (2014).","journal-title":"Oncol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70820-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70820-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70820-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:37:02Z","timestamp":1670348222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70820-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70820"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70820-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13750"}}